Gut microbial metabolites such as SCFAs, notably butyrate, improve myocardial repair by reducing fibrosis, inflammation, and enhancing cardiac function post-myocardial infarction, as supported by preclinical and translational studies, though specific clinical trial quantitative results are not reported.
Patients with myocardial infarction (MI), heart failure with preserved ejection fraction (HFpEF), metabolic myocardial diseases, and subjects with gut microbiota alterations
Cardiovascular diseases remain the leading global cause of morbidity and mortality, placing an escalating burden on health care systems and economies. While the gut microbiota is well recognized in atherosclerosis and cardiometabolic disorders, its influence on myocardial injury, repair, and regeneration is only beginning to emerge. Growing evidence reveals that gut microbes and their metabolites regulate myocardial health through intricate cross-organ networks, including the gut-brain-heart, gut-liver-heart, and gut-lung-heart axes. These findings suggest that the heart plays a key role in systemic host-microbe communication. Advances in metagenomics, metabolomics, and single-cell transcriptomics are now defining the molecular and cellular pathways by which microbial metabolites modulate immune tone, endothelial integrity, metabolic resilience, and cardiomyocyte survival. Studies in gnotobiotic models have established causal links between specific microbial taxa and myocardial outcomes while illuminating their roles in fibrosis resolution, angiogenesis, and regeneration. In this review, we synthesize current knowledge on the bidirectional gut-heart dialogue, emphasizing immunometabolic signaling, cross-organ integration, and regenerative mechanisms. We propose that coupling high-resolution multiomics with mechanistic modeling in controlled microbial systems will be pivotal for next-generation, microbiota-informed diagnostics, and therapeutics. We explore the emerging role of the gut-myocardium axis as both a driver of disease and as a promising modifiable therapeutic target and highlight a new frontier in precision cardiovascular medicine, with the potential to transform strategies for prevention, repair, and tissue regeneration.
Building similarity graph...
Analyzing shared references across papers
Loading...
Hung-Chih Chen
Institute of Biomedical Sciences, Academia Sinica
Tony W.H. Tang
Institute of Biomedical Sciences, Academia Sinica
Sumi Nani Novita Pasaribu
Institute of Biomedical Sciences, Academia Sinica
Circulation Research
University of Wisconsin–Madison
National Taiwan University
Kaohsiung Medical University
Building similarity graph...
Analyzing shared references across papers
Loading...
Chen et al. (Thu,) conducted a review in Patients with myocardial infarction (MI), heart failure with preserved ejection fraction (HFpEF), metabolic myocardial diseases, and subjects with gut microbiota alterations. Gut microbial metabolites such as SCFAs, notably butyrate, improve myocardial repair by reducing fibrosis, inflammation, and enhancing cardiac function post-myocardial infarction, as supported by preclinical and translational studies, though specific clinical trial quantitative results are not reported.
synapsesocial.com/papers/699010df2ccff479cfe57300 — DOI: https://doi.org/10.1161/circresaha.125.326978
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: